Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/166904
Title: | Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours |
Author: | Fernandes Neto, João M. Nadal, Ernest Bosdriesz, Evert Ooft, Salo N. Farré, Lourdes McLean, Chelsea Klarenbeek, Sjoerd Jurgens, Anouk Hagen, Hannes Wang, Liqin Felip, Enriqueta Martínez Martí, Alex Vidal-Bel, August Voest, Emile Wessels, Lodewyk F. A. van Tellingen, Olaf Villanueva Garatachea, Alberto Bernards, René |
Keywords: | Resistència als medicaments Tumors Drug resistance Tumors |
Issue Date: | 22-Jun-2020 |
Citation: | Neto, J. M. F., Nadal, E., Bosdriesz, E., Ooft, S. N., Farre, L., McLean, C., ... & Felip, E. (2020). Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours. Nature Communications, 11(1), 1-9. |
Abstract: | Resistance to targeted cancer drugs is thought to result from selective pressure exerted by a high drug dose. Partial inhibition of multiple components in the same oncogenic signalling pathway may add up to complete pathway inhibition, while decreasing the selective pressure on each component to acquire a resistance mutation. We report here testing of this Multiple Low Dose (MLD) therapy model in EGFR mutant NSCLC. We show that as little as 20% of the individual effective drug doses is sufficient to completely block MAPK signalling and proliferation when used in 3D (RAF + MEK + ERK) or 4D (EGFR + RAF + MEK + ERK) inhibidor combinations. Importantly, EGFR mutant NSCLC cells treated with MLD therapy do not develop resistance. Using several animal models, we find durable responses to MLD therapy without associated toxicity. Our data support the notion that MLD therapy could deliver clinical benefit, even for those having acquired resistance to third generation EGFR inhibidor therapy. |
Note: | Reproducció del document publicat a: https://doi.org/10.1038/s41467-020-16952-9 |
It is part of: | Nature Communications, 2020, vol. 11, num. 1, pp. 1-9 |
URI: | http://hdl.handle.net/2445/166904 |
Related resource: | https://doi.org/10.1038/s41467-020-16952-9 |
Appears in Collections: | Articles publicats en revistes (Patologia i Terapèutica Experimental) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
s41467-020-16952-9.pdf | 1.82 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License